Caldic Denmark A/S
CVR: 32478980
Secondary names: R2 MEDITALIA A/S, R2 PHARMACTIVE A/S, R2 Group Pharmaceuticals A/S
Caldic Denmark A/S is experiencing a declining revenue trend, with a notable drop from 240.9 million DKK in 2022 to 120.1 million DKK in 2024. Despite this decline, the company has maintained profitability, reporting a profit of 7.7 million DKK in 2024, although this is a decrease from 8.5 million DKK in 2022. The equity position has improved over the years, reaching 61.9 million DKK in 2024, indicating a strengthening balance sheet. However, the significant revenue drop raises concerns about its market position and ability to sustain growth within the pharmaceutical and healthcare wholesale industry.
AI-generated summary
Overview
Details
Contact
Purpose
Selskabets formål er at drive handels- og agenturvirksomhed samt anden hermed beslægtet virksomhed.
Location
Financials
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 120.1 mio. | 7.7 mio. | 83.3 mio. | 61.9 mio. | 10 | |
History
Ownership
Management
Directors
Board
Founders
Production units (1)
Similar companies
Companies in the same industry and area